Literature DB >> 9579302

Clozapine for the treatment of agitated-depressed patients with cognitive impairment: a report of three cases.

N Nacasch1, O T Dolberg, S Hirschmann, P Dannon, L J Grunhaus.   

Abstract

Clozapine, an atypical antipsychotic, is mainly approved for the treatment of resistant schizophrenia. However, a substantial body of evidence suggests that it might be useful in other psychiatric indications, such as treatment-resistant depression, Parkinson's disease, and dementia. In this report we present the cases of three patients hospitalized at the psychiatric division of the Sheba Medical Center, diagnosed with major depressive disorder with cognitive impairment, whose presenting symptom was agitation. These patients were nonresponders to various treatment modalities. However, treatment with clozapine brought about a favorable response.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9579302

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  2 in total

Review 1.  Clinical and economic factors in the treatment of behavioural and psychological symptoms of dementia.

Authors:  M E Hemels; K L Lanctôt; M Iskedjian; T R Einarson
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

2.  Identifying unexpected therapeutic targets via chemical-protein interactome.

Authors:  Lun Yang; Jian Chen; Leming Shi; Michael P Hudock; Kejian Wang; Lin He
Journal:  PLoS One       Date:  2010-03-08       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.